[go: up one dir, main page]

AU3407597A - Useful formulations of acid addition salt drugs - Google Patents

Useful formulations of acid addition salt drugs

Info

Publication number
AU3407597A
AU3407597A AU34075/97A AU3407597A AU3407597A AU 3407597 A AU3407597 A AU 3407597A AU 34075/97 A AU34075/97 A AU 34075/97A AU 3407597 A AU3407597 A AU 3407597A AU 3407597 A AU3407597 A AU 3407597A
Authority
AU
Australia
Prior art keywords
acid addition
addition salt
useful formulations
salt drugs
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU34075/97A
Other versions
AU738165B2 (en
Inventor
Ronald W. Pero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxi Gene Inc
Original Assignee
Oxi Gene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxi Gene Inc filed Critical Oxi Gene Inc
Publication of AU3407597A publication Critical patent/AU3407597A/en
Application granted granted Critical
Publication of AU738165B2 publication Critical patent/AU738165B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245Amino benzoic acid types, e.g. procaine, novocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU34075/97A 1996-06-28 1997-06-23 Useful formulations of acid addition salt drugs Ceased AU738165B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67334196A 1996-06-28 1996-06-28
US08/673341 1996-06-28
PCT/US1997/010829 WO1998000159A1 (en) 1996-06-28 1997-06-23 Useful formulations of acid addition salt drugs

Publications (2)

Publication Number Publication Date
AU3407597A true AU3407597A (en) 1998-01-21
AU738165B2 AU738165B2 (en) 2001-09-13

Family

ID=24702259

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34075/97A Ceased AU738165B2 (en) 1996-06-28 1997-06-23 Useful formulations of acid addition salt drugs

Country Status (7)

Country Link
EP (1) EP0954327A1 (en)
JP (1) JP2000516204A (en)
AU (1) AU738165B2 (en)
CA (1) CA2258965A1 (en)
IL (1) IL127691A0 (en)
WO (1) WO1998000159A1 (en)
ZA (1) ZA975755B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303671B1 (en) 1998-07-28 2001-02-23 Nicox Sa SALTS OF NITRIC ACID WITH ACTIVE DRUGS IN THE TREATMENT OF DISEASES OF THE RESPIRATORY SYSTEM
NZ523902A (en) * 2000-08-28 2004-05-28 Synthon Bv Paroxetine compositions and processes for making the same
JP2006028028A (en) * 2004-07-12 2006-02-02 Teikoku Medix Kk Oral medicinal composition
BRPI0503734A (en) * 2005-08-23 2007-04-27 Cristalia Prod Quimicos Farm pharmaceutical composition in ready-to-use morphine solution for injection and unit dosage form of morphine for epidural or intrathecal administration
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
JP6215970B2 (en) 2013-03-14 2017-10-18 フレゼニウス カービ ドイチュラント ゲーエムベーハー Injectable morphine preparation
CA2902346A1 (en) 2013-03-14 2014-09-18 Becton Dickinson France S.A.S. Packaging system for oxygen-sensitive drugs
CN118021718B (en) * 2024-04-12 2024-07-02 成都瑞尔医药科技有限公司 Propafenone hydrochloride injection and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2000025A (en) * 1977-05-14 1979-01-04 Pfizer Ltd Nitroimidazole formulations
US4536386B1 (en) * 1981-01-26 1995-03-07 Robins Co Inc A H Method of controlling emesis caused by cisplatin in cancer chemotherapy
PH22107A (en) * 1984-06-07 1988-06-01 Takeda Chemical Industries Ltd 3-pyrazolo(1,5-a)pyrdinium cephem compounds
US5260289A (en) * 1992-06-12 1993-11-09 Vitacain Pharmaceutical Co., Ltd. Composition for treating pain, method for treating pain and composition for reinforcing pain relief action

Also Published As

Publication number Publication date
EP0954327A1 (en) 1999-11-10
WO1998000159A1 (en) 1998-01-08
JP2000516204A (en) 2000-12-05
AU738165B2 (en) 2001-09-13
CA2258965A1 (en) 1998-01-08
ZA975755B (en) 1998-02-23
IL127691A0 (en) 1999-10-28

Similar Documents

Publication Publication Date Title
AU3455297A (en) Pharmaceutical composition containing acid addition salt of basic drug
AU5945396A (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
AU7547196A (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
AU7572196A (en) Pharmaceutical formulations
AU3574897A (en) Aqueous formulations of peptides
AU1307299A (en) Stable pharmaceutical compositions including ascorbic acid and methods of using same
PL335027A1 (en) Derivatives of arylsulphonylamino hydroxamic acid
AU4024295A (en) Amino acid derivatives of paclitaxel
AU2548097A (en) Formulations of ob protein
HU9502520D0 (en) Pharmaceutical use of substituted 4-phenyl-6-amino-nicotinic acid derivatives
HUP0000777A3 (en) Resolution of ritalinic acid salt
AU5761998A (en) Pharmaceutical aminophosphonic acid derivatives
PL340461A1 (en) Derivatives of isothiazocarboxylic acid
AU5647199A (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
AU2036297A (en) Topical formulations of aciclovir
AU3407597A (en) Useful formulations of acid addition salt drugs
AU3471995A (en) Pharmaceutical formulations comprising clavulanic acid or derivatives and an organic acid or salt
AU5443499A (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
AU1930097A (en) Slow-release pharmaceutical formulations containing mizolastin
AU5814696A (en) The preparation of carboxylic acid derivatives
AU6120298A (en) 2-peperazinone-1-acetic acid derivatives and their use
AU4959497A (en) Pharmaceutical composition containing bismuth-polyacrylic acid compounds
AU5560694A (en) Pharmaceutical formulations of ibuprofen
AU7286896A (en) N-sulphonyl and n-sulphinyl amino acid derivatives as microbicides
GB9525828D0 (en) Use of hetarylacetic acid derivatives

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired